To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Bezitramide is a narcotic analgesic. Bezitramide itself is a prodrug which is readily hydrolyzed in the gastrointestinal tract to its main metabolite, despropionyl-bezitramide. Bezitramide was discovered at Janssen Pharmaceutica in 1961. It is most commonly marketed under the trade name Burgodin®.
The drug was pulled from the shelves in the Netherlands in 2004 after fatal overdose cases, including one where a five year old child took one tablet from his mother's purse, ate it, and promptly died.
Bezitramide is regulated much the same as morphine in all known jurisdictions and is, surprisingly, a Schedule II rather than Schedule I narcotic under the United States' Controlled Substances Act of 1970. However, it has to this point never been marketed in the United States.
Other drugs which are legal for medical use in the US but not marketed up to this point in time include phenazocine, metopon, alphaprodine (formerly marketed as Nisentil) , anileridine (formerly marketed as Leritine), ethylmorphine (regulated like codeine and therefore preparations with other active ingredients can be Schedule III or Schedule V), isomethadone, levomethorphan, metazocine, piminodine (formerly marketed as Alvodine), racemethorphan, moramide intermediate (the most common moramide, the Schedule I dextromoramide was once marketed in the US as Dimorlin® for a short time in the 1950s), and racemorphan.
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Bezitramide". A list of authors is available in Wikipedia.|